- Details
- Christopher Wallis and Zachary Klaassen discuss the EV-201 study. EV-201 is a multicentre, single-arm, phase 2 study of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors. Dr. Wallis and Dr. Klaassen review Cohort 2 which included adults with an Eastern Cooperative Oncology Group performance status score of 2 or...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine publication titled The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. In this posthoc analysis the PRIMARY study evaluated the clinical significance of patterns of intra-prostatic PSMA activity, proposing a 5- point PRIMARY score to opti...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the publication entitled "Trends in Incidence of Metastatic Prostate Cancer in the US." Analysis of the emerging trends suggests that the incidence rates of metastatic prostate cancer have increased significantly and coincide temporally with the US Preventive Services Task Force (USPSTF) recommendations against prostate cancer screening across races...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication on the activity and adverse effects of Actinium-225 therapy, in advanced metastatic castrate resistant prostate cancer (mCRPC) patients, after the failure of their Lutetium-177 treatment. Dr. Wallis begins by discussing the topic of theranostics, and the difference between the beta-emitter, 177-Lutetium, and the alpha-emitter, 225-Actin...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recent paper entitled, “UpFront PSMA: A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer, a Clinical Trial Protocol.” Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc,...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, "Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer." In this comparative effectiveness study, immune checkpoint inhibitors were more effective than taxanes in patients with mCRPC when tumor mutational burden (TMB) was 10 mt/Mb...
|
- Details
- In this UroToday Journal Club, Drs Christopher Wallis and Zachary Klaassen present a Lancet Oncology publication titled Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Spinal cord compression is one of t...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer”. Dr. Wallis discusses DNA damage repair mutations and how they present in men with localized prostate cancer. They also discuss the specific genomic mutations seen most commonly in men with DNA damage repair mutations affecting their prosta...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss The Journal of Clinical Oncology publication entitled, "Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial." This trial evaluated the treatment effect of adding docetaxel to ADT + radiation therapy on the primary end point of overall...
|
